{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:42:37Z","timestamp":1790055757973,"version":"4.0.1"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sickle cell disease (SCD) is an inheritable hemoglobinopathy characterized by polymerization of hemoglobin S in red blood cells resulting in chronic hemolytic anemia, vaso-occlusive painful crisis, and multiorgan damage. In SCD, an increased reactive oxygen species (ROS) generation occurs both inside the red blood cells and inside the vascular lumen, which augment hemolysis and cellular adhesion. This review discusses the evolving body of literature on the role of ROS in the pathophysiology of SCD as well as some emerging therapeutic approaches to SCD with a focus on the reduction of ROS.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.440","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"440-446","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Evolving treatment paradigms in sickle cell disease"],"prefix":"10.1182","volume":"2017","author":[{"given":"Ramasamy","family":"Jagadeeswaran","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Illinois at Chicago, Chicago, IL; and"},{"name":"Jesse Brown Veterans Affairs Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rivers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Illinois at Chicago, Chicago, IL; and"},{"name":"Jesse Brown Veterans Affairs Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111703504372200_B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.14264","article-title":"New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?","volume":"175","author":"Oder","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703504372200_B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/iub.584","article-title":"Role of oxidative stress in the pathogenesis of sickle cell disease","volume":"64","author":"Chirico","year":"2012","journal-title":"IUBMB Life"},{"issue":"6","key":"2019111703504372200_B3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajh.21416","article-title":"Nutritional deficiencies in iron overloaded patients with hemoglobinopathies","volume":"84","author":"Claster","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111703504372200_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ars.2009.2978","article-title":"Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia","volume":"13","author":"Cho","year":"2010","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2019111703504372200_B5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbrc.2012.08.113","article-title":"Peroxiredoxin II is essential for preventing hemolytic anemia from oxidative stress through maintaining hemoglobin stability","volume":"426","author":"Han","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019111703504372200_B6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcmd.2011.01.002","article-title":"Assessment of oxidative stress in patients with sickle cell disease: the glutathione system and the oxidant-antioxidant status","volume":"46","author":"Gizi","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2019111703504372200_B7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.85.1.237","article-title":"Accelerated autoxidation and heme loss due to instability of sickle hemoglobin","volume":"85","author":"Hebbel","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111703504372200_B8","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.V78.10.2753.2753","article-title":"Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents","volume":"78","author":"Repka","year":"1991","journal-title":"Blood"},{"issue":"11","key":"2019111703504372200_B9","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2012-07-441188","article-title":"Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease","volume":"121","author":"George","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111703504372200_B10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2003.04781.x","article-title":"Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells","volume":"124","author":"Banerjee","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111703504372200_B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2017.02.003","article-title":"Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease","volume":"50","author":"Jagadeeswaran","year":"2017","journal-title":"Exp Hematol"},{"issue":"6","key":"2019111703504372200_B12","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111703504372200_B13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.20809","article-title":"Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload","volume":"82","author":"Fung","year":"2007","journal-title":"Am J Hematol"},{"issue":"26","key":"2019111703504372200_B14","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1073\/pnas.221292098","article-title":"Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease","volume":"98","author":"Aslan","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2019111703504372200_B15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1096\/fj.04-3218fje","article-title":"Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice","volume":"19","author":"Wood","year":"2005","journal-title":"FASEB J"},{"key":"2019111703504372200_B16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1749-6632.2000.tb06201.x","article-title":"Reactive species in sickle cell disease","volume":"899","author":"Aslan","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2019111703504372200_B17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.2005.05834.x","article-title":"Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants","volume":"132","author":"Amer","year":"2006","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111703504372200_B18","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2013-09-529420","article-title":"Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation","volume":"123","author":"Cardenes","year":"2014","journal-title":"Blood"},{"key":"2019111703504372200_B19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation-2015.1.426","article-title":"Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?","volume":"2015","author":"Field","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111703504372200_B20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V85.1.268.bloodjournal851268","article-title":"Sickle reticulocytes adhere to VCAM-1","volume":"85","author":"Gee","year":"1995","journal-title":"Blood"},{"issue":"10","key":"2019111703504372200_B21","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood.V92.10.3924","article-title":"Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes","volume":"92","author":"Sultana","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111703504372200_B22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2141.2009.07760.x","article-title":"Aminophospholipid translocase and phospholipid scramblase activities in sickle erythrocyte subpopulations","volume":"146","author":"Barber","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111703504372200_B23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/ajcn\/54.4.736","article-title":"Supplementation of patients with homozygous sickle cell disease with zinc, alpha-tocopherol, vitamin C, soybean oil, and fish oil","volume":"54","author":"Muskiet","year":"1991","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2019111703504372200_B24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcmd.2011.03.004","article-title":"Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia","volume":"47","author":"Silva","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2019111703504372200_B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia, I: Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111703504372200_B26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.mph.0000140651.65591.b8","article-title":"Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia","volume":"26","author":"Williams","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"22","key":"2019111703504372200_B27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.V128.22.1318.1318","article-title":"Phase 3 study of L-glutamine therapy in sickle cell anemia and sickle \u03b20-thalassemia subgroup analyses show consistent clinical improvement","volume":"128","author":"Niihara","year":"2016","journal-title":"Blood"},{"key":"2019111703504372200_B28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-662-45805-1_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"2019111703504372200_B29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111703504372200_B30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2710.2011.01276.x","article-title":"Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease","volume":"37","author":"Jordan","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2019111703504372200_B31","first-page":"66","article-title":"Evaluation of simvastatin antioxidant effects","volume":"107","author":"Ungureanu","year":"2003","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"5","key":"2019111703504372200_B32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.2010.08480.x","article-title":"A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction","volume":"153","author":"Hoppe","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703504372200_B33","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2011.054957","article-title":"Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia","volume":"97","author":"Bereal-Williams","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2019111703504372200_B34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3945\/ajcn.112.036319","article-title":"Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial","volume":"97","author":"Daak","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"2019111703504372200_B35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-0463.2011.02751.x","article-title":"Pilot study of omega-3 fatty acid supplements in sickle cell disease","volume":"119","author":"Okpala","year":"2011","journal-title":"APMIS"},{"issue":"4","key":"2019111703504372200_B36","doi-asserted-by":"crossref","first-page":"e0152895","DOI":"10.1371\/journal.pone.0152895","article-title":"Phase 1 study of a sulforaphane-containing broccoli sprout homogenate for sickle cell disease","volume":"11","author":"Doss","year":"2016","journal-title":"PLoS One"},{"issue":"17","key":"2019111703504372200_B37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/ars.2016.6638","article-title":"Oral monomethyl fumarate therapy ameliorates retinopathy in a humanized mouse model of sickle cell disease","volume":"25","author":"Promsote","year":"2016","journal-title":"Antioxid Redox Signal"},{"issue":"39","key":"2019111703504372200_B38","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1073\/pnas.1509158112","article-title":"Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation","volume":"112","author":"Keleku-Lukwete","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111703504372200_B39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jsm.12391","article-title":"Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis","volume":"11","author":"Musicki","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"2019111703504372200_B40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14057","article-title":"mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111703504372200_B41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.exphem.2015.06.008","article-title":"An international effort to cure a global health problem: a report on the 19th Hemoglobin Switching Conference","volume":"43","author":"Blobel","year":"2015","journal-title":"Exp Hematol"},{"issue":"22","key":"2019111703504372200_B42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood.V128.22.124.124","article-title":"Phase 1 evaluation of oral tetrahydrouridine-decitabine as non-cytotoxic epigenetic disease modification for sickle cell disease","volume":"128","author":"Molokie","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111703504372200_B43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2015.140749","article-title":"The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)","volume":"101","author":"Rivers","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111703504372200_B44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2016-10-746727","article-title":"Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons","volume":"129","author":"Ibanez","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111703504372200_B45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2015-02-626259","article-title":"The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice","volume":"126","author":"Cui","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111703504372200_B46","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111703504372200_B47","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2003-07-2209","article-title":"Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes","volume":"103","author":"Turhan","year":"2004","journal-title":"Blood"},{"key":"2019111703504372200_B48","first-page":"426","article-title":"Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Field","year":"2015"},{"issue":"5","key":"2019111703504372200_B49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703504372200_B50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2010.08150.x","article-title":"The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults","volume":"149","author":"Kalff","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111703504372200_B51","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2011.08630.x","article-title":"Regular automated erythrocytapheresis in sickle cell patients","volume":"154","author":"Driss","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111703504372200_B52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/trf.12875","article-title":"Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease","volume":"55","author":"Michot","year":"2015","journal-title":"Transfusion"},{"issue":"9","key":"2019111703504372200_B53","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/trf.14154","article-title":"From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease","volume":"57","author":"Ballas","year":"2017","journal-title":"Transfusion"},{"issue":"9","key":"2019111703504372200_B54","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"2019111703504372200_B55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00277-011-1404-z","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients","volume":"91","author":"Nur","year":"2012","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111703504372200_B56","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111703504372200_B57","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1055\/s-0037-1615948","article-title":"Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids","volume":"85","author":"Tomer","year":"2001","journal-title":"Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/440\/1251154\/hem00062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/440\/1251154\/hem00062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:48:01Z","timestamp":1574520481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/440\/21158\/Evolving-treatment-paradigms-in-sickle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.440","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}